A leading oncologist explores promising new breast cancer therapies in the drug development pipeline and advises healthcare providers on strategies to remain informed about the most current treatment guidelines and recommendations.
In R/R Marginal Zone Lymphoma, 90% Alive at 2 Years After Liso-Cel
June 24th 2025In a cohort of TRANSCEND FL, the chimeric antigen receptor T-cell therapy liso-cel showed a 95% overall response rate in relapsed marginal zone lymphoma, offering hope for improved patient outcomes in challenging cases.
Read More